Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients

Addiction

Volumn 101, Issue 9, 2006, Pages 1333-1338

  Justo, Dan ^a,b   Gal Oz, Amir ^b   Paran, Yael ^b   Goldin, Yelena ^b   Zeltser, David ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Methadone; Polymorphic ventricular tachycardia; Torsades de Pointes

Indexed keywords

LEVACETYLMETHADOL; METHADONE; OPIATE;

ADULT; AGE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HEART DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INFORMATION RETRIEVAL; KIDNEY FAILURE; LIVER CIRRHOSIS; MALE; MALNUTRITION; METHADONE TREATMENT; OPIATE ADDICTION; QT PROLONGATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; STARVATION; TORSADE DES POINTES;

ADULT; FEMALE; HEROIN DEPENDENCE; HUMANS; HYPOKALEMIA; KIDNEY FAILURE; METHADONE; MIDDLE AGED; NARCOTICS; RENAL INSUFFICIENCY; RISK FACTORS; TORSADES DE POINTES;

EID: 33746885502     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01512.x     Document Type: Review

References (52)

1. Roden D. M. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
2. Katchman A. N., McGroary K. A., Kilborn M. J., Kornick C. A., Manfredi P. L., Woosley R. L. et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 2002; 303: 688-94.
3. Seyler D. E., Borowitz J. L., Maickel R. P. Calcium channel blockade by certain opioids. Fundam Appl Toxicol 1983; 3: 536-42.
4. Van der Burgh C. A review of the drug abuse situation in the world. In: Epidemiologic trends in drug abuse, vol. II. Proceedings of the International Epidemiology Work Group on Drug Abuse. Rockville, MD: National Institute on Drug Abuse; 1999, p. 135-8.
5. Krantz M. J., Mehler P. S. Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004; 164: 277-88.
6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual report on the state of the drugs problems in the European Union. Lisbon: EMCDDA; 2001. Available at: http://www.emcdda.org [accessed 16 February 2003].
7. Krantz M. J., Lewkowiez L., Hays H., Woodroffe M. A., Robertson A. D., Mehler P. S. Torsade de Pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137: 501-4.
8. Gil M., Sala M., Anguera I., Chapinal O., Cervantes M., Guma J. R. et al. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003; 92: 995-7.
9. Vodoz J. F., Jaquier F., Lamy O. Torsade de Pointes: a severe and unknown adverse effect in a patient taking methadone. Schweiz Rundsch Med Prax 2003; 92: 1748-50.
10. Piguet V., Desmeules J., Ehret G., Stoller R., Dayer P. QT interval prolongation in patients on methadone with concomitant drugs. J Clin Psychopharmacol 2004; 24: 446-8.
11. Sticherling C., Schaer B. A., Ammann P., Maeder M., Osswald S. Methadone-induced Torsade de Pointes tachycardias. Swiss Med Wkly 2005; 135: 282-5.
12. Mokwe E. O., Ositadinma O. Torsade de Pointes due to methadone. Ann Intern Med 2003; 139: W64.
13. Al-Shakarshi J. S., Bent-Hansen L., Jensen G. B. Life-threatening, recurrent arrhythmia in patients on high-dose methadone treatment: Torsade de Pointes. Ugeskr Laeger 2004; 166: 3104-5.
14. Sanchez Hernandez A. M., Atienza Fernandez F., Arenal Maiz A., Gonzalez Torrecilla E., Puchol Calderon A., Almendral Garrote J. Torsades de Pointes during methadone treatment. Rev Esp Cardiol 2005; 58: 1230-2.
15. Hrovatin E., Zardo F., Brieda M., Dametto E., Piazza R., Antonini-Canterin F. et al. Long QT and Torsade de Pointes in a patient with acquired human immunodeficiency virus infection in multitherapy with drugs affecting cytochrome P450. Ital Heart J Suppl 2004; 5: 735-40.
16. De Bels D., Staroukine M., Devriendt J. Torsades de Pointes due to methadone. Ann Intern Med 2003; 139: E156.
17. Ostvold C., Topper M. Methadone-induced heart arrhythmia. Tidsskr Nor Laegeforen 2005; 125: 2021-2.
18. Krantz M. J., Rowan S. B., Mehler P. S. Cocaine-related Torsade de Pointes in a methadone maintenance patient. J Addict Dis 2005; 24: 53-60.
19. Rademacher S., Dietz R., Haverkamp W. QT prolongation and syncope with methadone, doxepin, and a beta-blocker. Ann Pharmacother 2005; 39: 1762-3.
20. Krantz M. J., Garcia J. A., Mehler P. S. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related Torsade de Pointes. Pharmacotherapy 2005; 25: 611-4.
21. Porter B. O., Coyne P. J., Smith W. R. Methadone-related Torsades de Pointes in a sickle cell patient treated for chronic pain. Am J Hematol 2005; 78: 316-7.
22. Walker P. W., Klein D., Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003; 103: 321-4.
23. Decerf J. A., Gressens B., Brohet C., Liolios A., Hantson P. Can methadone prolong the QT interval? Intens Care Med 2004; 30: 1690-1.
24. Pearson E. C., Woosley R. L. QT prolongation and Torsades de Pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 2005; 14: 747-53.
25. Almehmi A., Malas A. M., Yousufuddin M., Rosencrance J. G. Methadone-induced Torsade de Pointes in a patient with normal baseline QT interval. W V Med J 2004; 100: 147-8.
26. Khantzian E. J., Treece C. DSM-III psychiatric diagnosis of narcotic addicts. Recent findings. Arch Gen Psychiatry 1985; 42: 1067-71.
27. Woody G. E., McLellan A. T., Luborsky L., O'Brien C. P. Sociopathy and psychotherapy outcome. Arch Gen Psychiatry 1985; 42: 1081-6.
28. Rounsaville B. J., Weissman M. M., Kleber H., Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982; 39: 161-8.
29. Schrem S. S., Belsky P., Schwartzman D., Slater W. Cocaine-induced Torsades de Pointes in a patient with the idiopathic long QT syndrome. Am Heart J 1990; 120: 980-4.
30. Justo D. Invited comment. Acta Psychiatr Scand 2005; 112: 322.
31. Justo D., Prokhorov V., Heller K., Zeltser D. Torsade de Pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 2005; 111: 171-6.
32. McCarthy J. J., Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis 2001; 20: 19-31.
33. Rosenberg P. S., Biggar R. J. Trends in HIV incidence among young adults in the United States. JAMA 1998; 279: 1894-9.
34. Kay G. N., Plumb V. J., Arciniegas J. G., Henthorn R. W., Waldo A. L. Torsade de Pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 1983; 2: 806-17.
35. Napolitano C., Priori S. G., Schwartz P. J. Torsade de Pointes. Mechanisms and management. Drugs 1994; 47: 51-65.
36. Ahmed W., Flynn M. A., Alpert M. A. Cardiovascular complications of weight reduction diets. Am J Med Sci 2001; 321: 280-4.
37. Flockhart D. A., Oesterheld J. R. Cytochrome P450-mediated drug interactions. Child Adolesc Psychiatr Clin N Am 2000; 9: 43-76.
38. Nanavati K. A., Fisher S. D., Miller T. L., Lipshultz S. E. HIV-related cardiovascular disease and drug interactions. Am J Cardiovasc Drugs 2004; 4: 315-24.
39. Makkar R. R., Fromm B. S., Steinman R. T., Meissner M. D., Lehmann M. H. Female gender as a risk factor for Torsades de Pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-7.
40. Torp-Pedersen C., Moller M., Bloch-Thomsen P. E., Kober L., Sandoe E., Egstrup K. et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-65.
41. D'Aunno T., Folz-Murphy N., Lin X. Changes in methadone treatment practices: results from a panel study, 1988-95. Am J Drug Alcohol Abuse 1999; 25: 681-99.
42. Houltz B., Darpo B., Edvardsson N., Blomstrom P., Brachmann J., Crijns H. J. et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 21: 1044-57.
43. Bazzet H. C. An analysis of time relations of echocardiograms. Heart 1920; 7: 353-67.
44. Maremmani I., Pacini M., Cesaroni C., Lovrecic M., Perugi G., Tagliamonte A. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 2005; 11: 44-9.
45. Martell B. A., Arnsten J. H., Krantz M. J., Gourevitch M. N. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95: 915-8.
46. van Opstal J. M., Schoenmakers M., Verduyn S. C., de Groot S. H., Leunissen J. D., van Der Hulst F. F. et al. Chronic amiodarone evokes no Torsade de Pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001; 104: 2722-7.
47. Faggiano F., Vigna-Taglianti F., Versino E., Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; 3: CD002208.
48. Borowsky S. A., Lieber C. S. Interaction of methadone and ethanol metabolism. J Pharmacol Exp Ther 1978; 207: 123-9.
49. Vieweg W. V. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry 2003; 5: 205-15.
50. Vieweg W. V., Wood M. A. Tricyclic antidepressants, QT interval prolongation, and Torsade de Pointes. Psychosomatics 2004; 45: 371-7.
51. Krook A. L., Waal H., Hansteen V. Routine ECG in methadone-assisted rehabilitation is wrong prioritization. Tidsskr Nor Laegeforen 2004; 124: 2940-1.
52. Krantz M. J., Garcia J. A., Mehler P. S. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related Torsade de Pointes. Pharmacotherapy 2005; 25: 611-4.